Revaprazan

Drug Profile

Revaprazan

Alternative Names: Revanex; SB 641257; YH 1885; YH1885L

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Antiulcers; Isoquinolines; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Gastric ulcer; Gastritis
  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 03 Feb 2016 No recent reports on development identified - Phase-II for Gastro-oesophageal reflux in South Korea (PO)
  • 01 Apr 2014 Yuhan Corporation completes a phase II trial in non-erosive Gastro-oesophageal reflux in South Korea (NCT01750437)
  • 15 Jul 2013 Yuhan Corporation completes enrolment in a phase II trial for non-erosive Gastro-oesophageal reflux in South Korea (NCT01750437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top